Literature DB >> 20227158

The increase in seroprevalence to Toxocara canis in asthmatic children is related to cross-reaction with Ascaris suum antigens.

M A Muñoz-Guzmán1, B E del Río-Navarro, G Valdivia-Anda, F Alba-Hurtado.   

Abstract

BACKGROUND: It has been suggested that the presence of Toxocara canis larvae in lungs is an underlying factor in the onset of asthma. Although the association of asthma and seropositivity to Toxocara has been observed, there are no studies that indicate whether these antibodies are specific against T. canis antigens.
METHODS: Seroprevalence to T. canis excretion-secretion antigens (TcES Ag) were compared between asthmatic children (n=285) and non-asthmatic children (n=152), using IgG-ELISA and IgE-ELISA. The recognition patterns of TcES Ag were determined using Western blot (WB).
RESULTS: IgG-ELISA seroprevalence was 30.8% for asthmatic children and 19.7% for non-asthmatic children (p<0.05). IgE-ELISA seroprevalence was 7.7% for asthmatic children and 6.5% for non-asthmatic children, respectively (p>0.05). Sera of both groups positive to IgG-ELISA recognised 11 TcES Ag bands for IgG. No differences between the groups were observed regarding recognition patterns; the asthmatic group, however, presented significantly higher cross-reaction to Ascaris suum somatic antigens (AsS Ag) than the non-asthmatic group. Sixty-three sera from asthmatic children positive to IgG-ELISA were evaluated by WB for IgE and 58.7% revealed a recognition pattern for IgE. In the group of non-asthmatic children positive to IgG-ELISA, 80% presented IgE band recognition. No differences were observed between the groups regarding recognition patterns.
CONCLUSIONS: The results observed suggest that differences in seroprevalence determined by IgG-ELISA between groups of asthmatic and non-asthmatic children reported by other authors occur because of a higher frequency of cross-reaction in asthmatic children. 2009 SEICAP. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227158     DOI: 10.1016/j.aller.2009.09.007

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  6 in total

1.  Texas and Mexico: sharing a legacy of poverty and neglected tropical diseases.

Authors:  Peter J Hotez; Maria Elena Bottazzi; Eric Dumonteil; Jesus G Valenzuela; Shaden Kamhawi; Jaime Ortega; Samuel Ponce de Leon Rosales; Miguel Betancourt Cravioto; Roberto Tapia-Conyer
Journal:  PLoS Negl Trop Dis       Date:  2012-03-27

2.  Successful capture of Toxocara canis larva antigens from human serum samples.

Authors:  Aarón Rodríguez-Caballero; Mario Noé Martínez-Gordillo; Yolanda Medina-Flores; María Edith Medina-Escutia; Antonio Meza-Lucas; Dolores Correa; Silvia Caballero-Salazar; Martha Ponce-Macotela
Journal:  Parasit Vectors       Date:  2015-05-08       Impact factor: 3.876

3.  Detection of Specific Antibody Reactivity to Toxocara Larval Excretory-secretory Antigens in Asthmatic Patients (5-15 Years).

Authors:  Mahdi Mosayebi; Latif Moini; Reza Hajihossein; Mojtaba Didehdar; Zahra Eslamirad
Journal:  Open Microbiol J       Date:  2016-10-31

4.  Investigations for the Possible Use of a Monoclonal Antibody Produced against Strongyloides ratti Antigen as an Immunodiagnostic Reagent for Active Strongyloidiasis.

Authors:  Aliyu Mahmuda; Faruku Bande; Noor Abdulhaleem; Roslaini Abd Majid; Rukman Awang Hamat; Wan Omar Abdullah; Zasmy Unyah
Journal:  Iran J Parasitol       Date:  2018 Apr-Jun       Impact factor: 1.012

5.  Allergic asthma manifestations in human and seropositivity to Toxocara, a soil-transmitted helminth of carnivores: A case-control study and scoping review of the literature.

Authors:  Nasrin Bazargan; Azadeh Nasri Lari; Mehdi Borhani; Majid Fasihi Harandi
Journal:  Front Med (Lausanne)       Date:  2022-09-29

Review 6.  Toxocariasis in North America: a systematic review.

Authors:  Rachel M Lee; Laura B Moore; Maria Elena Bottazzi; Peter J Hotez
Journal:  PLoS Negl Trop Dis       Date:  2014-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.